Combating highly resistant emerging pathogen Mycobacterium abscessus and Mycobacterium tuberculosis with novel salicylanilide esters and carbamates
- PMID: 26210507
- DOI: 10.1016/j.ejmech.2015.07.001
Combating highly resistant emerging pathogen Mycobacterium abscessus and Mycobacterium tuberculosis with novel salicylanilide esters and carbamates
Abstract
In the Mycobacterium genus over one hundred species are already described and new ones are periodically reported. Species that form colonies in a week are classified as rapid growers, those requiring longer periods (up to three months) are the mostly pathogenic slow growers. More recently, new emerging species have been identified to lengthen the list, all rapid growers. Of these, Mycobacterium abscessus is also an intracellular pathogen and it is the most chemotherapy-resistant rapid-growing mycobacterium. In addition, the cases of multidrug-resistant Mycobacterium tuberculosis infection are also increasing. Therefore there is an urgent need to find new active molecules against these threatening strains. Based on previous results, a series of salicylanilides, salicylanilide 5-chloropyrazinoates and carbamates was designed, synthesized and characterised. The compounds were evaluated for their in vitro activity on M. abscessus, susceptible M. tuberculosis H37Rv, multidrug-resistant (MDR) M. tuberculosis MDR A8, M. tuberculosis MDR 9449/2006 and on the extremely-resistant Praha 131 (XDR) strains. All derivatives exhibited a significant activity with minimum inhibitory concentrations (MICs) in the low micromolar range. Eight salicylanilide carbamates and two salicylanilide esters exhibited an excellent in vitro activity on M. abscessus with MICs from 0.2 to 2.1 μM, thus being more effective than ciprofloxacin and gentamicin. This finding is potentially promising, particularly, as M. abscessus is a threateningly chemotherapy-resistant species. M. tuberculosis H37Rv was inhibited with MICs from 0.2 μM, and eleven compounds have lower MICs than isoniazid. Salicylanilide esters and carbamates were found that they were effective also on MDR and XDR M. tuberculosis strains with MICs ≥1.0 μM. The in vitro cytotoxicity (IC50) was also determined on human MonoMac-6 cells, and selectivity index (SI) of the compounds was established. In general, salicylanilide derivatives substituted by halogens on both salicyl and aniline rings showed better activity, than 4-benzoylaniline derivatives. The ester or carbamate bond formation of parent salicylanilides mostly retained or improved antimycobacterial potency with moderate selectivity.
Keywords: Antimycobacterial activity; Multidrug-resistant Mycobacterium tuberculosis; Mycobacterium abscessus; Salicylanilide; Salicylanilide 5-chloropyrazinoate; Salicylanilide carbamate.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Salicylanilide N-monosubstituted carbamates: Synthesis and in vitro antimicrobial activity.Bioorg Med Chem. 2016 Mar 15;24(6):1322-30. doi: 10.1016/j.bmc.2016.02.004. Epub 2016 Feb 4. Bioorg Med Chem. 2016. PMID: 26879856
-
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.Bioorg Med Chem. 2014 Aug 1;22(15):4073-82. doi: 10.1016/j.bmc.2014.05.064. Epub 2014 Jun 5. Bioorg Med Chem. 2014. PMID: 24953953
-
Salicylanilide carbamates: antitubercular agents active against multidrug-resistant Mycobacterium tuberculosis strains.Bioorg Med Chem. 2010 Feb;18(3):1054-61. doi: 10.1016/j.bmc.2009.12.055. Epub 2009 Dec 29. Bioorg Med Chem. 2010. PMID: 20060303
-
Salicylanilide ester prodrugs as potential antimicrobial agents--a review.Curr Pharm Des. 2011;17(32):3494-505. doi: 10.2174/138161211798194521. Curr Pharm Des. 2011. PMID: 22074422 Review.
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
Cited by
-
Small molecule QF84139 ameliorates cardiac hypertrophy via activating the AMPK signaling pathway.Acta Pharmacol Sin. 2022 Mar;43(3):588-601. doi: 10.1038/s41401-021-00678-5. Epub 2021 May 9. Acta Pharmacol Sin. 2022. PMID: 33967278 Free PMC article.
-
Multitargeting Compounds: A Promising Strategy to Overcome Multi-Drug Resistant Tuberculosis.Molecules. 2020 Mar 9;25(5):1239. doi: 10.3390/molecules25051239. Molecules. 2020. PMID: 32182964 Free PMC article. Review.
-
NTM drug discovery: status, gaps and the way forward.Drug Discov Today. 2018 Aug;23(8):1502-1519. doi: 10.1016/j.drudis.2018.04.001. Epub 2018 Apr 7. Drug Discov Today. 2018. PMID: 29635026 Free PMC article. Review.
-
Looking beyond Typical Treatments for Atypical Mycobacteria.Antibiotics (Basel). 2020 Jan 3;9(1):18. doi: 10.3390/antibiotics9010018. Antibiotics (Basel). 2020. PMID: 31947883 Free PMC article. Review.
-
Synthesis and biological evaluation of novel 5-chloro-N-(4-sulfamoylbenzyl) salicylamide derivatives as tubulin polymerization inhibitors.Medchemcomm. 2018 Jul 26;9(9):1511-1528. doi: 10.1039/c8md00214b. eCollection 2018 Sep 1. Medchemcomm. 2018. PMID: 30288225 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical